Current Research:

CJC-1295, a synthetic growth hormone-releasing hormone (GHRH) analog, has gained attention for its potential therapeutic benefits in stimulating growth hormone (GH) and insulin-like growth factor-I (IGF-I) secretion. Pulsatile GH secretion is crucial for many physiological functions, and while short-term GHRH infusions have shown promise in enhancing GH pulsatility and increasing IGF-I, the limitations of GHRH’s short half-life hinder its therapeutic application.

However, CJC-1295 addresses this limitation with its extended half-life of 8 days due to its permanent binding to endogenous albumin post-injection. Research aimed to assess GH pulsatility following a single injection of CJC-1295 and determine its correlation with IGF-I production increase. Results demonstrated that CJC-1295 administration increased GH secretion while preserving pulsatility, with both basal (trough) and mean GH levels significantly elevated. Despite the unaltered frequency and magnitude of GH secretory pulses, the overall GH secretion and subsequent IGF-I levels substantially increased.

 Notably, the marked enhancement of trough GH levels underscores the importance of continuous GHRH stimulation in augmenting IGF-I production. These findings suggest that long-acting GHRH preparations like CJC-1295 hold promise for clinical use, particularly in patients with intact pituitary GH secretory capability, offering a potential avenue for therapeutic intervention in conditions characterized by disrupted GH and IGF-I dynamics.

Minimum quantity: 1-Gram